Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fleming

Showing results (521-530 of 700) with videos related to

Pageof 70
Sort By:
Gynecologic Oncology|April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II ConsortiaH Hirte, S Lheureux, G F Fleming, et al.
Annals of Tropical Medicine and Parasitology|February 1, 1985
Malaria and haemoglobin genotype in young northern Nigerian childrenA F Fleming, A Akintunde, E D Attai, et al.
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
International Journal of Cancer|December 15, 1986
Antibodies to HTLV-I in Nigerian blood-donors, their relatives and patients with leukaemias, lymphomas and other diseasesA F Fleming, R Maharajan, M Abraham, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2018
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian CancerTatsuo Matsuda, Matthias Leisegang, Jae-Hyun Park, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 1, 1983
Malaria and splenomegalyA Bryceson, Y M Fakunle, A F Fleming, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Gynecologic Oncology|May 1, 2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancerJennifer Taylor Veneris, Kathleen M Darcy, Paulette Mhawech-Fauceglia, et al.
Pageof 70

Showing results (521-530 of 700) with videos related to

Sort By:
Pageof 70
Gynecologic Oncology|April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II ConsortiaH Hirte, S Lheureux, G F Fleming, et al.
Annals of Tropical Medicine and Parasitology|February 1, 1985
Malaria and haemoglobin genotype in young northern Nigerian childrenA F Fleming, A Akintunde, E D Attai, et al.
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
International Journal of Cancer|December 15, 1986
Antibodies to HTLV-I in Nigerian blood-donors, their relatives and patients with leukaemias, lymphomas and other diseasesA F Fleming, R Maharajan, M Abraham, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2018
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian CancerTatsuo Matsuda, Matthias Leisegang, Jae-Hyun Park, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 1, 1983
Malaria and splenomegalyA Bryceson, Y M Fakunle, A F Fleming, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Gynecologic Oncology|May 1, 2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancerJennifer Taylor Veneris, Kathleen M Darcy, Paulette Mhawech-Fauceglia, et al.
Pageof 70